{"title":"利拉鲁肽和二甲双胍联合疗法增强 2 型糖尿病和冠心病患者胰岛功能的研究","authors":"Chunxiao Yang","doi":"10.26689/par.v7i6.5566","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the impact of combining liraglutide with metformin on the enhancement of pancreatic islet function in patients with type 2 diabetes and coronary heart disease. Methods: 60 patients with type 2 diabetes and coronary heart disease admitted from February 2022 to August 2023 were selected as research subjects. They were randomly assigned to either control or treatment groups, with 30 patients in each. The control group received metformin alone, while the treatment group received liraglutide in combination with metformin. Various indicators, including blood sugar levels, pancreatic islet function, and cardiac function between the two groups were compared. Results: The results of FPG, 2hPG, HbA1c, HOMA-IR, NT-proBNP, and LVEDD in the treatment group were lower than those in the control group, whereas the values of FINS, HOMA-β, E/A, and LVEF in the treatment group were higher than those in the control group (P < 0.05). Conclusion: The use of liraglutide in combination with metformin significantly benefits patients with type 2 diabetes and coronary heart disease. It leads to improved pancreatic islet function, better blood sugar control, and enhanced cardiac function. This combination therapy is recommended for clinical adoption.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Study on Enhancing Pancreatic Islet Function in Type 2 Diabetes and Coronary Heart Disease Patients with Liraglutide and Metformin Combination Therapy\",\"authors\":\"Chunxiao Yang\",\"doi\":\"10.26689/par.v7i6.5566\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To investigate the impact of combining liraglutide with metformin on the enhancement of pancreatic islet function in patients with type 2 diabetes and coronary heart disease. Methods: 60 patients with type 2 diabetes and coronary heart disease admitted from February 2022 to August 2023 were selected as research subjects. They were randomly assigned to either control or treatment groups, with 30 patients in each. The control group received metformin alone, while the treatment group received liraglutide in combination with metformin. Various indicators, including blood sugar levels, pancreatic islet function, and cardiac function between the two groups were compared. Results: The results of FPG, 2hPG, HbA1c, HOMA-IR, NT-proBNP, and LVEDD in the treatment group were lower than those in the control group, whereas the values of FINS, HOMA-β, E/A, and LVEF in the treatment group were higher than those in the control group (P < 0.05). Conclusion: The use of liraglutide in combination with metformin significantly benefits patients with type 2 diabetes and coronary heart disease. It leads to improved pancreatic islet function, better blood sugar control, and enhanced cardiac function. This combination therapy is recommended for clinical adoption.\",\"PeriodicalId\":20511,\"journal\":{\"name\":\"Proceedings of Anticancer Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Proceedings of Anticancer Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26689/par.v7i6.5566\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of Anticancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26689/par.v7i6.5566","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A Study on Enhancing Pancreatic Islet Function in Type 2 Diabetes and Coronary Heart Disease Patients with Liraglutide and Metformin Combination Therapy
Objective: To investigate the impact of combining liraglutide with metformin on the enhancement of pancreatic islet function in patients with type 2 diabetes and coronary heart disease. Methods: 60 patients with type 2 diabetes and coronary heart disease admitted from February 2022 to August 2023 were selected as research subjects. They were randomly assigned to either control or treatment groups, with 30 patients in each. The control group received metformin alone, while the treatment group received liraglutide in combination with metformin. Various indicators, including blood sugar levels, pancreatic islet function, and cardiac function between the two groups were compared. Results: The results of FPG, 2hPG, HbA1c, HOMA-IR, NT-proBNP, and LVEDD in the treatment group were lower than those in the control group, whereas the values of FINS, HOMA-β, E/A, and LVEF in the treatment group were higher than those in the control group (P < 0.05). Conclusion: The use of liraglutide in combination with metformin significantly benefits patients with type 2 diabetes and coronary heart disease. It leads to improved pancreatic islet function, better blood sugar control, and enhanced cardiac function. This combination therapy is recommended for clinical adoption.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
